



Public Health Subcommittee

Measles, Mumps, and Rubella (MMR) Booster Immunization Practices

February 10, 2020




Overview

- **Membership**
- **Review Tasking**
- **Summary of Subcommittee Activities to Date**
- **Areas of Interest**
- **Way Ahead**



Membership



**Georges Benjamin,
MD**



**Wilsie Bishop,
DPA**



**Craig Blakely,
PhD, MPH**



**John Clements,
PhD**



**Charles Dodd,
DVM, PhD**



**John Groopman,
PhD**



**RADM (Ret)
H. Clifford Lane, MD**



**James Lockey,
MD, MS**



**Russell Luepker,
MD, MS**

Tasking


On November 7, 2019, the Assistant Secretary of Defense for Health Affairs directed the Defense Health Board (“the Board”) to **provide recommendations to the Department of Defense (DoD) on the optimal way to minimize the risk of mumps in our armed forces and maintain medical readiness.**



Tasking (2/4)

- In 2010, the Board reviewed this topic for the Navy and **did not recommend a universal third MMR immunization strategy:**

- Current practices should be continued.
- Selective immunization for those with:
 - < 2 documented MMR vaccines, or
 - Low titers of measles or rubella neutralizing antibodies
- Consider universal MMR vaccination if the risk of mumps outbreaks increase.





Tasking (3/4)

- In 2019, there were at least 2 major incidences of mumps across the Services:



USS Fort McHenry

- 28 cases of illness out of 703 crew members
- Quarantined at sea for about 4 months



173rd Airborne Division of the Army

- 10 cases of illness, 1 confirmed case of mumps
- Ring vaccination of about 200 Soldiers



Tasking (4/4)

- Determine if **universal administration of MMR vaccine at accessions** and a booster vaccine for current service members is warranted based on recent events. Specifically:

- Review scientific literature and epidemiologic trends to quantify current and future risk to medical readiness from mumps outbreaks
- Determine if current immunization policy is sufficient to mitigate potential risk and, if not, recommend best practices to mitigate that risk.
- Provide any additional recommendations to inform policy, such as impact to budgetary and logistical requirements



Summary of Activities to Date

- A “kick off” preparatory meeting with the Public Health Subcommittee is scheduled for February 25-26, 2020
- DHB staff have conducted 5 informational teleconferences with subject matter experts, epidemiologists, preventive medicine/public health responders, and policy makers on the MMR vaccine



Areas of Interest

Topic	Discussion Points
Science of mumps vaccine	<ul style="list-style-type: none">• Waning immunity• Challenges of serological testing
Epidemiological burden of mumps	<ul style="list-style-type: none">• U.S. and global surveillance• Surveillance within the Military
Current recommendations	<ul style="list-style-type: none">• Current recommendations from the Centers for Disease Control and Prevention
DHA Immunization Policies	<ul style="list-style-type: none">• Current DHA policies and practice• Challenges of immunization practice



Way Ahead

- Report expected to be briefed and deliberated at the next Board meeting in May 2020



Questions ?